radretumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 464379793

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = fibronectin

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1253180-81-2

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 6JVA140UB4

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.{{cite web | title = Radretumab (L19-131I) | publisher = Philogen | url = http://www.philogen.com/en/products/pipeline/radretumab-l19-131i_13.html | archive-url = https://web.archive.org/web/20171106133539/http://www.philogen.com/en/products/pipeline/radretumab-l19-131i_13.html | archive-date = 6 November 2017 }}{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf }}{{cite journal | vauthors = Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G | title = Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies | journal = Journal of Nuclear Medicine | volume = 53 | issue = 6 | pages = 922–7 | date = June 2012 | pmid = 22577235 | doi = 10.2967/jnumed.111.101006 | s2cid = 26518175 | doi-access = free }}